Edition:
United States

People: Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

3.50USD
18 Apr 2019
Change (% chg)

$-0.03 (-0.85%)
Prev Close
$3.53
Open
$3.52
Day's High
$3.57
Day's Low
$3.43
Volume
56,598
Avg. Vol
106,593
52-wk High
$7.16
52-wk Low
$3.31

Tooman, Craig 

Mr. Craig A. Tooman is the President, Chief Executive Officer, Director of the company. he was Chief Financial Officer, Treasurer of Aratana Therapeutics Inc. He was a member of our Board of Directors from April 2012 to November 2013. Mr. Tooman previously served as the Chief Executive Officer of Avanzar Medical, Inc., a privately-held company focused on commercial oncology opportunities, from February 2012 until November 2014. Mr. Tooman was also the founder and principal of Stockbourne LLC, a firm that provides strategic business and financial advisory services, a position he held from January 2011 to November 2013. From July 2010 to January 2011, Mr. Tooman was the Senior Vice President of Finance and Chief Financial Officer of Ikaria Inc., a biotherapeutics company. From January 2005 to July 2010, Mr. Tooman was the Executive Vice President of Finance and Chief Financial Officer at Enzon Pharmaceuticals, a biopharmaceutical company. Prior to that, Mr. Tooman was the Senior Vice President of Strategic Planning and Corporate Communications at ILEX Oncology, Inc. and the Vice President of Investor Relations at Pharmacia Corporation. Since 2011, Mr. Tooman has served on the Board of Directors of Insite Vision Incorporated, a publicly-traded ophthalmological company, and he is currently the Chairman of its audit committee and a member of its compensation committee. He has a B.A. in Economics from Kalamazoo College and M.B.A. in Finance from the University of Chicago.

Basic Compensation

Total Annual Compensation, USD 350,000
Restricted Stock Awards, USD 95,900
Long-Term Incentive Plans, USD --
All Other, USD 463,188
Fiscal Year Total, USD 909,088

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --